MedPath

Shortwave Life Sciences' Psilocybin Combination Shows Positive Pre-Clinical Safety Results for Anorexia Treatment

• Shortwave Life Sciences reports positive pre-clinical safety results for its psilocybin-based combination drug aimed at treating anorexia nervosa. • The study, conducted with Science in Action, showed no adverse effects in rats at elevated doses of the drug administered buccally. • This milestone supports Shortwave's advancement towards human trials and validates its patent-pending buccal delivery system for mental health treatments. • The company's approach targets rapid drug absorption, bypassing liver and gut degradation, potentially transforming treatment for metabolic and psychiatric challenges.

Shortwave Life Sciences has announced positive pre-clinical safety results for its proprietary psilocybin-based combination drug, marking a significant step toward human trials for the treatment of anorexia. The study, conducted in collaboration with Science in Action, demonstrated the safety of the drug combination at elevated doses when administered buccally.
The pre-clinical pharmacodynamics study involved administering varying doses (0.23ml, 0.5ml, and 1ml) of Shortwave's combination drug to three groups of rats. The results indicated no adverse effects, weight changes, or behavioral changes following the psychedelic effects. According to the company, all subjects remained healthy throughout the trial, providing a strong foundation for clinical development.

Key Findings from the Pre-Clinical Study

  • No adverse events or vital sign changes were reported across all groups.
  • The safety profile of the psilocybin-based combination drug was confirmed at elevated doses.
  • The study reaffirmed the efficiency of Shortwave's buccal delivery platform.
Rivki Stern Youdkevich, CEO of Shortwave, stated, "This is a monumental step forward for Shortwave... We are proud of the positive outcomes from this rigorous pre-clinical trial, further validating our patent-pending drug combination and buccal delivery system."
This achievement follows the International PCT Examining Committee's acknowledgement of Shortwave's patent claims for its mucoadhesive buccal film. The platform is designed for rapid absorption, bypassing liver and gut degradation, and holds potential for patients facing metabolic and psychiatric challenges.

Addressing Unmet Needs in Mental Health

Shortwave Life Sciences is focused on developing therapies for unmet medical needs in mental health. The company's approach involves drug development and aims to introduce solutions for mental health disorders worldwide. The positive pre-clinical results drive Shortwave closer to human trials, with the goal of reshaping the mental health treatment landscape, particularly in the field of eating disorders.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Laxxon Medical's Oral GLP-1 Agonist LXM.2 Shows Promise in Pilot Study

Laxxon Medical's LXM.2, an oral GLP-1 agonist, demonstrated a 10-fold increase in bioavailability compared to existing products in a pilot study.
The LXM.2 tablet incorporates a permeation enhancer and enteric coating to optimize drug absorption in the small intestine.

First Clinical Trial of DM199 Launched to Combat Preeclampsia

Stellenbosch University initiates a clinical trial for DM199, a novel drug targeting the root cause of preeclampsia, a severe pregnancy complication.
DM199, a synthetic form of tissue-kallikrein-1, aims to improve blood vessel health by addressing endothelial dysfunction, unlike current treatments focused on managing blood pressure.

BioAdaptives' Zeranovia Receives IRB Approval for Human Clinical Trial in Weight Management

BioAdaptives Inc. has secured Institutional Review Board (IRB) approval to commence a human clinical trial for its weight management product, Zeranovia™.
The initial phase of the trial, to be conducted in Las Vegas, Nevada, will focus on confirming dosing and identifying potential side effects.

BioAdaptives' Zeranovia Receives IRB Approval for Human Clinical Trial in Weight Management

BioAdaptives Inc. has secured IRB approval to begin a human clinical trial for Zeranovia, its weight management product, marking a significant step in its development.
The initial phase of the trial will focus on confirming appropriate dosing and identifying any potential new side effects associated with Zeranovia.

Silo Pharma's SPC-15 Demonstrates Promising Preclinical Results for Stress-Related Disorders

Silo Pharma's SPC-15, a dual-action treatment targeting 5-HT4R and NMDAR, shows enhanced efficacy in preclinical studies for stress-induced behaviors.
Animal models demonstrated significant improvements in behavioral outcomes related to severe stress-induced conditions with the SPC-15 treatment.

Velocity Clinical Research Trials New Weight Loss Pill and Injection Methods

Velocity Clinical Research is conducting a clinical trial to evaluate different dosages and delivery methods of weight loss medications.
The trial includes both injectable medications and a new pill form, aiming to provide more options for weight management.

Tryptamine Therapeutics Progresses Psilocin Drug Trials for Treatment-Resistant Depression

Tryptamine Therapeutics is advancing its clinical trials for psilocin, a psychedelic drug, targeting treatment-resistant depression.
The company is focusing on optimizing the delivery and therapeutic effects of psilocin to improve patient outcomes.

Lexaria's Oral Tirzepatide Pilot Study Begins Dosing, Evaluating DehydraTECH Delivery

Lexaria Bioscience has initiated dosing in a human pilot study evaluating an oral formulation of tirzepatide, processed with their DehydraTECH technology.
The study compares the oral DehydraTECH-tirzepatide to injected Zepbound, assessing tolerability, pharmacokinetics, and blood sugar control in healthy volunteers.

Pfizer's Ponsegromab Shows Promise in Phase 2 Trial for Cancer Cachexia

Pfizer's ponsegromab demonstrated positive results in a Phase 2 trial for treating cancer cachexia, a wasting condition affecting millions worldwide.
The study showed that patients receiving ponsegromab experienced improvements in body weight, muscle mass, quality of life, and physical function.

Paradoxical Intervention: A Novel Strategy to Overload Cancer Cells

Researchers are initiating a clinical trial using a 'paradoxical intervention' strategy to treat advanced colorectal cancer by overstimulating oncogenic signaling.
The approach involves LB-100, a PP2A inhibitor, to stress cancer cells, followed by adavosertib, a WEE1 inhibitor, to prevent DNA damage repair.

Reference News

[1]
Positive Pre-Clinical Result Drive to Human Trials | Company Announcement - Investegate
investegate.co.uk · Sep 19, 2024

Shortwave Life Sciences announces positive pre-clinical results for its psilocybin-based drug combination, showing safet...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy